ACM
ABUS icon

Aquatic Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Aquatic Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.9K Buy
18,112
+5,767
+47% +$25.3K ﹤0.01% 1110
2026
Q1 		$55.6K Buy
+12,345
New +$54K ﹤0.01% 1164
2022
Q4 		– Sell
-21,600
Closed -$41K – 1300
2022
Q3 		$41K Buy
21,600
+19,500
+929% +$45.9K ﹤0.01% 909
2022
Q2 		$6K Buy
+2,100
New +$5.37K ﹤0.01% 1027

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Aquatic Capital Management's ABUS Position: Q2 2026 in Review

Aquatic Capital Management increased its Arbutus Biopharma (ABUS) stake by 47% in Q2 2026, buying an estimated $25.3K and bringing the position to 18,112 shares worth $86.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1110.

Aquatic Capital Management first reported a position in ABUS in Q2 2022 and has held it in 4 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Aquatic Capital Management held 18,112 shares of Arbutus Biopharma worth $86.9K as of Q2 2026.
  • Aquatic Capital Management bought 5,767 Arbutus Biopharma shares in Q2 2026, an estimated $25.3K.
  • Arbutus Biopharma made up ﹤0.01% of Aquatic Capital Management's portfolio in Q2 2026, its #1110 holding.
  • Aquatic Capital Management first reported a position in Arbutus Biopharma in Q2 2022 and has held it in 4 quarters since.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.